Data di Pubblicazione:
2015
Abstract:
BACKGROUND
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea
Tipologia CRIS:
Articolo su Rivista
Keywords:
Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Female; Humans; Hydroxyurea; Janus Kinases; Kaplan-Meier Estimate; Male; Middle Aged; Organ Size; Polycythemia Vera; Pyrazoles; Remission Induction; Spleen; Thrombocytopenia; Medicine (all)
Elenco autori:
Vannucchi, Alessandro M.; Kiladjian, Jean Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Mesa, Ruben; He, Shui; Jones, Mark M.; Garrett, William; Li, Jingjin; Pirron, Ulrich; Habr, Dany; Verstovsek, Srdan
Link alla scheda completa:
Pubblicato in: